It is noteworthy that SYK, an oncogenic kinase and a potential therapeutic target for Small-cell lung cancer and hematologic neoplasms [34–36], was over-expressed in subtype I (Table 2). This evidence concerns the gene SYK and hematopoietic and lymphoid system neoplasm.